Treatment of Staphylococcus aureus endocarditis using moxifloxacin

被引：10

作者：

Berrington, AW ^{[1
]}

Koerner, RJ

Perry, JD

Bain, HH

Gould, FK

机构：

[1] Freeman Rd Hosp, Dept Med Microbiol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England

[2] Freeman Rd Hosp, Dept Paediat, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England

来源：

INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY | 2001年 / 291卷 / 03期

关键词：

moxifloxacin; endocarditis; quinolone; Staphylococcus aureus; therapy;

D O I：

10.1078/1438-4221-00126

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The conventional treatment of staphylococcal endocarditis requires in-patient administration, is inconvenient, and is potentially toxic. Increasing experience with well-absorbed, well-tolerated and highly active agents such as the new quinolones has prompted interest in their use as therapeutic alternatives for the treatment of such infections. We describe a case of staphylococcal endocarditis which failed to respond to conventional therapy, but where the addition of moxifloxacin, an 8-methoxyquinolone, was curative.

引用

页码：237 / 239

页数：3

共 10 条

[1] MEDICAL-TREATMENT OF INFECTIVE ENDOCARDITIS - GENERAL-PRINCIPLES [J].

BESNIER, JM ;

CHOUTET, P .

EUROPEAN HEART JOURNAL, 1995, 16 :72-74

[2]

DWORKIN RJ, 1989, LANCET, V2, P1071

[3] Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains [J].

Jones, ME ;

Visser, MR ;

Klootwijk, M ;

Heisig, P ;

Verhoef, J ;

Schmitz, FJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :421-423

[4] CIPROFLOXACIN AND RIFAMPIN, ALONE AND IN COMBINATION, FOR THERAPY OF EXPERIMENTAL STAPHYLOCOCCUS-AUREUS ENDOCARDITIS [J].

KAATZ, GW ;

SEO, SM ;

BARRIERE, SL ;

ALBRECHT, LM ;

RYBAK, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) :1184-1187

[5] Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and streptococci of Lancefield Groups A and G [J].

MacGowan, AP ;

Bowker, KE ;

Wootton, M ;

Holt, HA .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (06) :761-766

[6] Penetration of moxifloxacin into peripheral compartments in humans [J].

Müller, M ;

Stass, H ;

Brunner, M ;

Möller, JG ;

Lackner, E ;

Eichler, HG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) :2345-2349

[7]

Simmons NA, 1998, HEART, V79, P207

[8] Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci [J].

von Eiff, C ;

Peters, G .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (04) :569-573

[9] ANTIBIOTIC-TREATMENT OF ADULTS WITH INFECTIVE ENDOCARDITIS DUE TO STREPTOCOCCI, ENTEROCOCCI, STAPHYLOCOCCI, AND HACEK MICROORGANISMS [J].

WILSON, WR ;

KARCHMER, AW ;

DAJANI, AS ;

TAUBERT, KA ;

BAYER, A ;

KAYE, D ;

BISNO, AL ;

FERRIERI, P ;

SHULMAN, ST ;

DURACK, DT .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (21) :1706-1713

[10] Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration [J].

Wise, R ;

Andrews, JM ;

Marshall, G ;

Hartman, G .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1508-1510

← 1 →